Healthcare & Life Sciences
Stemcentrx
United States
acquired
acquired
Stage
1
Investors
About
Developed precision therapies and diagnostics that target cancer stem cells in solid tumors using a stem cell–centric discovery approach. The company focused on oncology drug discovery and was acquired by AbbVie in 2016.
Explore Stemcentrx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.